Nephrology Medical News about Microvascular Complications

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A New Perspective on Therapeutic Inhibition of Advanced Glycation in Diabetic Microvascular Complications: Common Downstream Endpoints Achieved Through Disparate Therapeutic Approaches
American Journal of Nephrology, 06/30/09

Sourris KC et al. - A commonality among the chemically disparate compounds that inhibit the formation and accumulation of advanced glycation end products (AGEs) or their signalling pathways is their end organ protection in experimental models of diabetes complications. Although this group of therapeutics are structurally and functionally distinct with numerous mechanisms of action, the most important factor governing their therapeutic capability is clearly their ability to alleviate the tissue burden of advanced glycation, rather than the biochemical mechanism by which this is achieved.

<< Previous
Arteriovenous fistula in an autotransplanted kidney segment:...

Next >>
Assessment of cardiovascular risk in waiting-listed renal...

Why does diabetes offer protective effects against prostate cancer? The possible role of its microvascular complications
Medical Hypotheses, 11/04/09 Relevance Score: 65%

Clinical characteristics of patients with type 2 diabetes mellitus at the time of insulin initiation: INSTIGATE observational study in Spain
Acta Diabetologia, 10/29/09 Relevance Score: 65%

Advanced age as a contraindication to microvascular decompression for drug-resistant trigeminal neuralgia: evidence of prejudice?
Neurological Sciences, 10/09/09 Relevance Score: 65%

Role of endothelial progenitor cells in diabetes mellitus
Expert Review of Endocrinology & Metabolism, 11/16/09 Relevance Score: 64%

Variant Intraneural Vein-Trigeminal Nerve Relationships: An Observation During Microvascular Decompression Surgery for Trigeminal Neuralgia
Neurosurgery, 10/19/09 Relevance Score: 64%